Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

Tirzepatide has already been filed for approval ... Now, top-line data from the SURMOUNT-1 trial which pitted the drug against placebo in more than 2,500 overweight or obese people without ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fractyl Health, Inc. Common Stock misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.44. Operator: Good afternoon, and ...